<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593346</url>
  </required_header>
  <id_info>
    <org_study_id>03-1205 / 201011816</org_study_id>
    <nct_id>NCT00593346</nct_id>
  </id_info>
  <brief_title>Evaluation of Accelerated Partial Breast Brachytherapy</brief_title>
  <official_title>Evaluation of Accelerated Partial Breast Brachytherapy as the Sole Method of Radiation Therapy for Stage 0, 1 and II Lymph Node Negative Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the past two decades, breast conserving therapy (BCT) has become a major treatment
      modality for Stage I and II breast carcinoma. The major advantages of breast conserving
      therapy are superior cosmetic outcome and the reduced emotional and psychological trauma
      afforded by this procedure compared with conventional mastectomy. The principal disadvantage
      of BCT is its more complex and prolonged treatment regimen requiring approximately 6 weeks of
      external beam radiation therapy that poses problems for some patients such as the working
      woman, elderly patients, and those who live at a significant distance from a treatment
      center. These factors, along with the patient's geographic location, result in a smaller
      fraction of the patients who currently meet eligibility criteria for BCT actually receiving
      it, despite its cosmetic and probable psychological advantages. The logistical problems of
      BCT are primarily related to the protracted course of external beam radiation therapy to the
      whole breast. While some investigators reported what they believe to be acceptable local
      control rates in carefully selected patients treated by wide local excision without radiation
      therapy, the criteria for patient selection are controversial and poorly defined and probably
      restrict the access of many patients to breast conserving therapy.

      If previous observations are valid and breast irradiation following tylectomy exerts its
      maximal effect in eradicating occult disease remaining in the immediate vicinity of the
      tylectomy site, can radiation therapy be directed only to the tissue surrounding the excision
      cavity of the breast, using brachytherapy alone? If so, the entire course of radiation
      therapy could be delivered over a 4 to 7 day period immediately following tylectomy and/or
      axillary dissection, thus markedly reducing treatment time. Brachytherapy also inherently
      provides a higher central dose to the volume most at risk for recurrence. Cosmetic outcome
      after the use of a brachytherapy boost after external whole breast radiotherapy is comparable
      or slightly inferior to electron beam boost radiation therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the local control, cosmetic results, quality of life, and
      complication rates of brachytherapy when used as the sole method of radiation therapy for
      patients with stage 0,I, and II carcinoma of the breast treated with tylectomy, with
      histologically assessed negative surgical margins, N0 axillary nodes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control Using Ipsilateral Breast Tumor Recurrence Rates</measure>
    <time_frame>2 years after treatment completion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Control as Measured by Ipsilateral Breast Tumor Recurrence Rates</measure>
    <time_frame>5 years after treatment completion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Control Using Disease-free Survival Rates</measure>
    <time_frame>2 years after treatment completion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Control Using Disease-free Survival Rates</measure>
    <time_frame>5 years after treatment completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Completion</measure>
    <time_frame>2 years</time_frame>
    <description>-QOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC breast cancer module QLQ-BR23 questionnaires. QLQ-C30 is composed of 30 questions. QLQ-BR23 consists of 23 questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excellent-good Cosmetic Outcomes - Patient Reported</measure>
    <time_frame>3 years after completion of therapy</time_frame>
    <description>Both the participants and the treating radiation oncologist qualitatively rated cosmesis as excellent, good, fair, or poor over time and ascribed a cause for changes in cosmesis.
The global cosmetic result were scored on a 4-point scare where 0=excellent result (no difference), 1=good (small difference), 2=fair result (moderate difference) and 3=poor result (large difference).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excellent-good Cosmetic Outcomes - Physician Reported</measure>
    <time_frame>3 years after completion of therapy</time_frame>
    <description>Both the participants and the treating radiation oncologist qualitatively rated cosmesis as excellent, good, fair, or poor over time and ascribed a cause for changes in cosmesis. Cosmetic outcome was evaluated quantitatively by percentage of breast retraction assessment (pBRA).
The global cosmetic result were scored on a 4-point scale where 0=excellent result (no difference), 1=good (small difference), 2=fair result (moderate difference) and 3=poor result (large difference).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impressions of the Cause of Cosmesis Changes Over Time - Patient Reported</measure>
    <time_frame>3 years</time_frame>
    <description>-Patients filled out a form &quot;Patient Evaluation of the Treated Breast&quot;. On this form the patients were asked to compare the memory of what their breast looked like after surgery but before radiation and to compare that memory to the appearance of the breast after radiation. The patients were then asked if their breast changes were due to:
caused mostly by radiation
caused by both the radiation and surgery, but mostly by the radiation
caused by both the radiation and surgery, but mostly by the surgery
caused mostly by the surgery
can't judge which treatment caused the change
there are no changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmesis Outcome as Measured by Percentage of Breast Retraction Assessment (pBRA)</measure>
    <time_frame>Pre-treatment and 3 years</time_frame>
    <description>-Cosmetic outcome was evaluated quantitatively by percentage of breast retraction assessment (pBRA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or Absence of Complications</measure>
    <time_frame>5 years after treatment completion</time_frame>
    <description>As defined by number of participants who experienced breast infection and symptomatic fat necrosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Mastectomy After Completion of Initial Breast-conserving Treatment</measure>
    <time_frame>5 years after treatment completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Grade 3-4 Toxicities</measure>
    <time_frame>Up to 1 year from completion of therapy</time_frame>
    <description>RTOG acute and late toxicity grading system and via a visual analog scale for pain assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Accelerated partial breast brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <description>brachytherapy (radioactive implants)</description>
    <arm_group_label>Accelerated partial breast brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AJCC stage 0, I, or II (TisN0, T1N0, T2N0 = 3 cm) histologically confirmed carcinoma
             of the breast, treated with tylectomy. Axillary sampling is required only for cases of
             invasive cancers. Tumor size is determined by the pathologist. Clinical size may be
             used if the pathologic size is indeterminate.

          -  Signed study-specific informed consent for participation in the study.

          -  Negative, or close but negative, inked histologic margins of tylectomy or reexcision
             specimen to be confirmed prior to placing the brachytherapy catheters. Margins
             generally are positive if there is invasive or noninvasive tumor at the inked
             resection margin, close but negative if the tumor is within 2 mm of the inked margin
             and negative if the tumor is at least 2 mm away from the inked edge.

          -  Negative post-tylectomy or post-reexcision mammography if cancer presented with
             malignancy-associated microcalcifications; no remaining suspicious microcalcifications
             in the breast before brachytherapy.

          -  For patients with invasive cancer, no positive axillary lymph nodes with at least 6
             axillary lymph nodes sampled or a negative sentinel node.

          -  Invasive ductal, lobular, medullary, papillary, colloid (mucinous),or tubular
             histologies. Noninvasive ductal carcinoma in situ.

          -  Chemotherapy or hormonal therapy planned for = 2 weeks after removal of brachytherapy
             catheters is permitted. Hormonal therapy is allowed during brachytherapy at treating
             radiation oncologist's decision.

          -  Negative pregnancy test for premenopausal patients with an intact uterus

        Exclusion Criteria:

          -  Patients with distant metastases.

          -  Patients with in-situ lobular carcinoma or nonepithelial breast malignancies such as
             sarcoma or lymphoma.

          -  Patients with proven multicentric carcinoma (tumors in different quadrants of the
             breast, or tumors separated by at least 4 cm) with other clinically or
             radiographically suspicious areas in the ipsilateral breast unless confirmed to be
             negative for malignancy by biopsy.

          -  Patients who are pregnant or lactating.

          -  Patients with histologically confirmed positive axillary nodes in the ipsilateral
             axilla. Palpable or radiographically suspicious contralateral axillary,
             supraclavicular, infraclavicular, or internal mammary nodes, unless there is
             histologic confirmation that these nodes are negative for tumor.

          -  Prior non-hormonal therapy for the present breast cancer, including radiation therapy
             or chemotherapy.

          -  Patients with systemic lupus erythematosis, scleroderma, or dermatomyositis with a CPK
             level above normal or with an active skin rash.

          -  Patients with coexisting medical conditions in whom life expectancy is &lt; 2 years.

          -  Patients with psychiatric or addictive disorders that would preclude obtaining
             informed consent or completing the full series of high dose rate brachytherapy
             treatments on an outpatient basis.

          -  Patients with Paget's disease of the nipple.

          -  Patients with skin involvement, regardless of tumor size.

          -  Patients with a breast unsatisfactory for brachytherapy. For example, if there is
             little breast tissue remaining between the skin and pectoralis muscle after surgery,
             placement of catheters is technically problematic.

          -  Patients with tylectomies so extensive that the cosmetic result is fair or poor prior
             to brachytherapy.

          -  Surgical margins which cannot be microscopically assessed or are positive at
             pathological evaluation.

          -  Any previously treated contralateral breast carcinoma or synchronous bilateral breast
             carcinoma.

          -  Other malignancy, except non-melanoma skin cancer, ≤ 5 years prior to participation in
             this study; the disease free interval from any prior carcinoma must be continuous.

          -  Time between final definitive breast procedure to radioactive source loading of the
             brachytherapy catheters is greater than 8 weeks.

          -  Patients with diffuse (&gt; 1 quadrant or &gt;5 cm in diameter) suspicious
             microcalcifications.

          -  Patients with suspicious microcalcifications remaining on the post-tylectomy mammogram
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imran Zoberi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>January 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <results_first_submitted>April 13, 2015</results_first_submitted>
  <results_first_submitted_qc>May 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2015</results_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened to participant enrollment on March 12, 2004 and closed to participant enrollment on 12/22/2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Accelerated Partial Breast Bracytherapy</title>
          <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Accelerated Partial Breast Brachytherapy</title>
          <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="40" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Residence at diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Urban area</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urban cluster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rural</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor location</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Upper outer quadrant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper inner quadrant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower outer quadrant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower inner quadrant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pathologic tumor stage</title>
          <description>Tis: Carcinoma in situ. T1mic: Microinvasive ductal carcinoma T1a: Tumor &gt;1 mm but ≤5 mm in greatest dimension. T1b: Tumor &gt;5 mm but ≤10 mm in greatest dimension. T1c: Tumor &gt;10 mm but ≤20 mm in greatest dimension. T2: Tumor &gt;20 mm but ≤50 mm in greatest dimension.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Tis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1mic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sentinel lymph node biopsy</title>
          <description>Only for patients with invasive cancer</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Local Control Using Ipsilateral Breast Tumor Recurrence Rates</title>
        <time_frame>2 years after treatment completion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Brachytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Local Control Using Ipsilateral Breast Tumor Recurrence Rates</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Completion</title>
        <description>-QOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC breast cancer module QLQ-BR23 questionnaires. QLQ-C30 is composed of 30 questions. QLQ-BR23 consists of 23 questions.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Brachytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Completion</title>
          <description>-QOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC breast cancer module QLQ-BR23 questionnaires. QLQ-C30 is composed of 30 questions. QLQ-BR23 consists of 23 questions.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6-8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-8 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Excellent-good Cosmetic Outcomes - Patient Reported</title>
        <description>Both the participants and the treating radiation oncologist qualitatively rated cosmesis as excellent, good, fair, or poor over time and ascribed a cause for changes in cosmesis.
The global cosmetic result were scored on a 4-point scare where 0=excellent result (no difference), 1=good (small difference), 2=fair result (moderate difference) and 3=poor result (large difference).</description>
        <time_frame>3 years after completion of therapy</time_frame>
        <population>82 participants had cosmetic outcome data through 3 years of follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Brachytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Excellent-good Cosmetic Outcomes - Patient Reported</title>
          <description>Both the participants and the treating radiation oncologist qualitatively rated cosmesis as excellent, good, fair, or poor over time and ascribed a cause for changes in cosmesis.
The global cosmetic result were scored on a 4-point scare where 0=excellent result (no difference), 1=good (small difference), 2=fair result (moderate difference) and 3=poor result (large difference).</description>
          <population>82 participants had cosmetic outcome data through 3 years of follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-4 months after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Excellent-good Cosmetic Outcomes - Physician Reported</title>
        <description>Both the participants and the treating radiation oncologist qualitatively rated cosmesis as excellent, good, fair, or poor over time and ascribed a cause for changes in cosmesis. Cosmetic outcome was evaluated quantitatively by percentage of breast retraction assessment (pBRA).
The global cosmetic result were scored on a 4-point scale where 0=excellent result (no difference), 1=good (small difference), 2=fair result (moderate difference) and 3=poor result (large difference).</description>
        <time_frame>3 years after completion of therapy</time_frame>
        <population>82 participants had cosmetic outcome data through 3 years of follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Brachytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Excellent-good Cosmetic Outcomes - Physician Reported</title>
          <description>Both the participants and the treating radiation oncologist qualitatively rated cosmesis as excellent, good, fair, or poor over time and ascribed a cause for changes in cosmesis. Cosmetic outcome was evaluated quantitatively by percentage of breast retraction assessment (pBRA).
The global cosmetic result were scored on a 4-point scale where 0=excellent result (no difference), 1=good (small difference), 2=fair result (moderate difference) and 3=poor result (large difference).</description>
          <population>82 participants had cosmetic outcome data through 3 years of follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-4 months after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impressions of the Cause of Cosmesis Changes Over Time - Patient Reported</title>
        <description>-Patients filled out a form &quot;Patient Evaluation of the Treated Breast&quot;. On this form the patients were asked to compare the memory of what their breast looked like after surgery but before radiation and to compare that memory to the appearance of the breast after radiation. The patients were then asked if their breast changes were due to:
caused mostly by radiation
caused by both the radiation and surgery, but mostly by the radiation
caused by both the radiation and surgery, but mostly by the surgery
caused mostly by the surgery
can't judge which treatment caused the change
there are no changes</description>
        <time_frame>3 years</time_frame>
        <population>82 participants had cosmetic outcome data through 3 years of follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Brachytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Impressions of the Cause of Cosmesis Changes Over Time - Patient Reported</title>
          <description>-Patients filled out a form &quot;Patient Evaluation of the Treated Breast&quot;. On this form the patients were asked to compare the memory of what their breast looked like after surgery but before radiation and to compare that memory to the appearance of the breast after radiation. The patients were then asked if their breast changes were due to:
caused mostly by radiation
caused by both the radiation and surgery, but mostly by the radiation
caused by both the radiation and surgery, but mostly by the surgery
caused mostly by the surgery
can't judge which treatment caused the change
there are no changes</description>
          <population>82 participants had cosmetic outcome data through 3 years of follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Radiation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No cosmetic changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cosmesis Outcome as Measured by Percentage of Breast Retraction Assessment (pBRA)</title>
        <description>-Cosmetic outcome was evaluated quantitatively by percentage of breast retraction assessment (pBRA)</description>
        <time_frame>Pre-treatment and 3 years</time_frame>
        <population>82 participants had cosmetic outcome data through 3 years of follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Brachytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cosmesis Outcome as Measured by Percentage of Breast Retraction Assessment (pBRA)</title>
          <description>-Cosmetic outcome was evaluated quantitatively by percentage of breast retraction assessment (pBRA)</description>
          <population>82 participants had cosmetic outcome data through 3 years of follow-up.</population>
          <units>percentage of breast retraction</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.35" lower_limit="6.49" upper_limit="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.64" lower_limit="6.68" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Local Control as Measured by Ipsilateral Breast Tumor Recurrence Rates</title>
        <time_frame>5 years after treatment completion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Brachytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Local Control as Measured by Ipsilateral Breast Tumor Recurrence Rates</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Local Control Using Disease-free Survival Rates</title>
        <time_frame>2 years after treatment completion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Brachytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Local Control Using Disease-free Survival Rates</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Local Control Using Disease-free Survival Rates</title>
        <time_frame>5 years after treatment completion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Brachytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Local Control Using Disease-free Survival Rates</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence or Absence of Complications</title>
        <description>As defined by number of participants who experienced breast infection and symptomatic fat necrosis.</description>
        <time_frame>5 years after treatment completion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Brachytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence or Absence of Complications</title>
          <description>As defined by number of participants who experienced breast infection and symptomatic fat necrosis.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breast infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fat necrosis (symptomatic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Mastectomy After Completion of Initial Breast-conserving Treatment</title>
        <time_frame>5 years after treatment completion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Bracytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Mastectomy After Completion of Initial Breast-conserving Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Grade 3-4 Toxicities</title>
        <description>RTOG acute and late toxicity grading system and via a visual analog scale for pain assessment.</description>
        <time_frame>Up to 1 year from completion of therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Partial Breast Brachytherapy</title>
            <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Grade 3-4 Toxicities</title>
          <description>RTOG acute and late toxicity grading system and via a visual analog scale for pain assessment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute skin - Grade 3/4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute breast infection - Grade 3/4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute subcutaneous - Grade 3/4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late skin - Grade 3/4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late subcutaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late heart - Grade 3/4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late pulmonary - Grade 3/4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the start of treatment through 1 year after completion of treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Accelerated Partial Breast Bracytherapy</title>
          <description>Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>RTOG Acute/Late</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute breast infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute skin</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Acute subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Late skin</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Late subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Imran Zoberi, M.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-8525</phone>
      <email>izoberi@radonc.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

